Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 450 E 29th St Fl 15 NEW YORK NY 10016-8367 |
Tel: | N/A |
Website: | https://meiragtx.com |
IR: | See website |
Key People | ||
Alexandria Forbes President, Chief Executive Officer, Director | Richard Giroux Chief Financial Officer, Chief Operating Officer | Robert J. Wollin General Counsel, Secretary |
Stuart Naylor Chief Development Officer | Robert K. Zeldin Chief Medical Officer |
Business Overview |
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren's Syndrome; AAV-GAD for the treatment of Parkinson's Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy. |
Financial Overview |
For the fiscal year ended 31 December 2023, MeiraGTx Holdings PLC revenues decreased 12% to $14M. Net loss decreased 35% to $84M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Foreign currency loss increase from $9.5M (expense) to $9.3M (income), Interest income increase from $777K to $2.3M (income). |
Employees: | 419 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $264.09M as of Dec 31, 2023 |
Annual revenue (TTM): | $14.02M as of Dec 31, 2023 |
EBITDA (TTM): | -$123.33M as of Dec 31, 2023 |
Net annual income (TTM): | -$84.03M as of Dec 31, 2023 |
Free cash flow (TTM): | -$125.54M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 64,306,613 as of Apr 9, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |